Can-Fite BioPharma (CANF) Reports Q1 Loss of NIS0.21/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CANF Hot Sheet
Join SI Premium – FREE
Can-Fite BioPharma (NYSE: CANF) reported Q1 EPS of (NIS0.21), versus (NIS0.06) reported last year. Revenue for the quarter came in at NIS214 thousand, versus NIS0 reported last year.
For earnings history and earnings-related data on Can-Fite BioPharma (CANF) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ACM Research (ACMR) Tops Q3 EPS by 6c ; Offers Guidance
- GigaCloud Technology Inc. (GCT) Tops Q3 EPS by 68c
- EPAM Systems (EPAM) Tops Q3 EPS by 11c, Beats on Revenue; Offers FY26 EPS Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
